Summary The effects of single doses of misonidazole (MISO) on blood flow and vascular volume in the SaFA and CaNT tumours and normal tissues of the mouse have been studied. MISO was administered in the dose range 250-1,000mg kg-and blood flow measured at different times after MISO by the 86RbCl extraction technique. Vascular volume was assessed by the distribution of 51Cr-labelled red blood cells. MISO at doses of 500 mg kg -or greater decreased flow in both tumours by up to 60% within 2 h. Flow remained reduced for up to 24 h. Similar but less profound changes were seen in the skin, although flow had recovered by 24 h. Only slight changes were seen in muscle, and none in kidney. The apparent loss of flow in tumours seen after large single doses of MISO may have important implications for its use as a chemosensitizer.
Misonidazole (MISO), a hypoxic cell radiosensitizer in vivo and in vitro Fowler et al., 1976) can also act as a chemosensitizer, potentiating the effects of various chemotherapeutic agents (McNally, 1982; Millar, 1982; Siemann, 1984) . In a recent study of the effects of MISO combined with melphalan on the vasculature of a murine sarcoma (Murray et al., 1987) we presented evidence that this combination of drugs profoundly affected vascular structure and function at doses which in combination produced significant growth delay. Our results, obtained using a fluorescent dye (Hoechst 33342) perfusion technique, indicated that MISO alone might be largely responsible for these vascular effects. We have therefore examined the effects of MISO on vascular function in the same tumour model using alternative techniques to measure both vascular volume and blood flow. The aim of these studies was to (a) corroborate our earlier observations, (b) determine the time course and dose-dependence of these effects, and (c) extend these studies to another tumour. In addition we have compared the effect on the sarcoma with that on several normal tissues, in an attempt to determine whether the observed effects were the result of a direct action on the tumour vasculature, or of a more general physiological effect.
Materials and methods

Tumours
The SaFA sarcoma was transplanted by trocar as 1 mm3 pieces subcutaneously onto the backs of WHT/Gy f BSVS mice. The anaplastic carcinoma CaNT was transplanted s.c. on to CBA/Ht Gy f TO mice by injection of a cell suspension in saline, obtained by mechanical disruption of a tumour.
Drug treatment
Misonidazole (MISO, Roche Ltd), was administered by i.p. injection of a solution of the drug dissolved in sterile saline at a series of concentrations representing total doses ranging from 250-1,000omgkg-1 Vascular perfusion estimated by Hoechst 33342 Vascular perfusion of the SaFA tumour was assessed at different times (2, 12 and 24 h) after MISO treatment. One minute before sacrifice, tumour-bearing mice were injected intravenously with the fluorescent DNA-binding dye Hoechst 33342, dissolved in saline to a concentration of 4 mg ml -1, and administered at a dosage of 40 mg kg-1 (Murray et al., 1987) . Tumours were excised and frozen for serial sectioning. Nikon microscope equipped with epifluorescence, and the percentage perfused volume was estimated by Chalkley point counting of the Hoechst-outlined vessels (Smith et al., 1987; Murray et al., 1987) . Only the SaFA tumour was assessed in this way as Hoechst 33342 diffuses rapidly throughout normal tissues, presumably due to the abundance of normal vasculature, making point counting almost impossible.
Relative blood flow estimated by 86RbCt extraction Relative blood flow was estimated in tumours and normal tissues by the 86RbCl extraction technique (Sapirstein, 1958) .
At 1 min prior to sacrifice, mice were injected with 50 pl of a saline solution of 86RbCl (Amersham Intrnational PLC) containing a total activity of 185 KBq. Mice were sacrificed as described above and tissues collected, weighed and counted for radioactivity. Relative blood flow is expressed as percent of cardiac output per gram of tissue. Total dpm in the dissected tissue is divided by the total dpm injected, after subtracting the amount of radioactivity remaining in the tail, which is assumed not to have entered the circulation.
As the emission characteristics of 51Cr and 86Rb differ sufficiently to be distinguished by a suitable scintillation counter, it was possible to estimate radioactivity from both isotopes in the same tissue sample. Thus blood volume (5'Cr) and relative blood flow (86Rb) could be determined for the same tumour or normal tissue sample by sequential injection of the two isotopes at 30 min (5 1Cr) and 1 min (86Rb) prior to sacrifice.
Vascular volume estimated by 51Cr-labelled red blood cells Vascular volume of tumours and normal tissues was also measured by estimating the proportion of red blood cells, previously labelled with 51Cr, in various tissues 30min after intravenous injection (Song & Levitt, 1970 biguillulln, UMMUSU III VdhUUI;dI-VUIUIIIC WILII IIIL;I-UUSIIlg ut3sr, (Figure 3b ). Although flow was reduced at 24 h at the highest dose of MISO this was not significantly different from controls.
Effect of MISO on vascular parameters of normal tissues Figure 4 shows how both 86RbCl extraction ( Figure 4a ) and '1Cr-rbc volume ( Figure 4b ) varied with time after MISO at 1,000 mg kg-1 in several normal tissues of WHT mice as well as the SaFA tumour. The profound drop in flow in both skin (P<0.02) and SaFA tumour (P<0.05) at 2 h after MISO treatment is clearly seen in Figure 3a , while muscle and kidney were essentially unaffected. At 24h after treatment relative blood flow remained reduced in the tumour compared to normal tissues which had either recovered to control level (skin, kidney) or risen, above control level (muscle). By 48 h flow in all tissues was slightly below control levels. Figure 4b shows, that apart from skin, effects of MISO on vascular volume of normal tissues were less pronounced than on relative blood flow. Once again kidney showed no significant changes over a 48 h period. Nor did the tumour or muscle show significant deviations from control values. Skin demonstrated an early fall in vascular volume followed by a large increase above control at 24 (P<0.05) and 48h after treatment. 
Discussion
MISO is known to reduce core temperature, respiration rate and heart rate in mice at doses in excess of 500 mg kg-1 (Conroy et al., 1980; Chin & Rauth, 1981; Gomer & Johnson, 1979) . There have been no reports concerning the effects of MISO on blood flow perse, although it has been suggested that the effects of MISO at high doses are 'vascular' in nature (Conroy et al., 1980; Murray et al., 1987) . In general physiological parameters such as respiration rate and core temperature appear to return to near normal by 6-8 h after administration of MISO at doses in excess of 500mg kg-1. We believe the highly significant reduction in relative blood flow seen in two different tumours at 2 h after injection of MISO reflects a peripheral vasoconstriction due to the drop in body temperature: effects were observed in skin and muscle, whilst kidney was unaffected. The proportionally greater drop in tumour perfusion than in skin may then be due to the inability of the tumour to respond in an active manner to the drop in blood flow or pressure around it. High internal resistance to flow, coupled with vessel collapse due to raised interstitial pressure (Falk, 1978) might contribute further to the reduction in tumour blood flow. The small changes seen in 5"Cr-rbc vascular volume also suggest however that a degree of vasoconstriction is coupled with a drop in cardiac output, as the drop in flow appears to be greater than might be anticipated simply from the vascular volume changes. At 24 h after MISO there appears to be a compensatory increase in both flow and vascular volume in normal tissues, in some cases above control values. This vasodilation has been previously observed microscopically in the subepithelium of the rabbit trachea at periods of 24 h or longer after MISO treatment (Albertsson et al., 1985) . In spite of this increase flow remains reduced in the tumour. This phenomenon might be explained by assuming that the tumour behaves passively and blood flow, in analogy with electrical current, follows the path of least resistance. Our previous microscopic observations with a basement membrane-staining antibody (Murray et al., 1987) suggested that there was a real decrease in vascular volume 24 and 48 h later, perhaps due to vessel collapse. This is partly supported by the 51Cr-rbc results, which indicate a drop of around 20% in tumour vascular volume at 24 and 48 h after MISO treatment. Once again, it is difficult to compare the techniques directly; whereas we may assume that the antibody to basement membrane stains blood vessels of all sizes (Barsky et al., 1983) , the distribution of 51Cr-labelled rbcs may be skewed in favour of larger vessels, underestimating the contribution of very fine capillaries in the tumour. Therefore, the evidence suggests that there may be changes in the tumour vasculature per se at later times, which contribute to the persistent diminution of blood flow. These observations are perhaps best summarized in Figure 5 which shows blood flow in the SaFA tumour expressed relative to that in skin. At 2h perfusion is reduced in both skin and tumour. The flow ratio is lowest at 24 h, by which time skin has already recovered but tumour flow has not. By 48 h the tumour has started to perfuse normally again and the ratio returns to normal.
Another possible mechanism of vascular damage may be through a direct action on endothelial cells. MISO is cytotoxic to hypoxic cells in vitro and in vivo (Hall & RoizinTowle, 1975; Stratford & Adams, 1977) . High doses of MISO alone can induce massive necrosis in certain mouse tumours (Brown, 1977) Randhawa et al. (1985) have examined the effects of MISO on melphalan pharmacokinetics and show a substantial increase in the total exposure of tumour to melphalan as a result of simultaneous MISO treatment (see Table II ). We have previously hypothesized that the 'trapping' of melphalan by MISO-induced vascular collapse was partly responsible for the resulting growth delay (Murray et al., 1987) , and this hypothesis is currently being tested using vaso-active drugs such as hydralazine, which reduces blood flow in the SaFA tumour and potentiates the effects of melphalan as assessed by regrowth delay, but which by itself is not cytotoxic (Murray & Randhawa, unpublished agents. The results were equivocal; in one case the sensitizer enhancement ratio; that is the dose of cytotoxin required to achieve a given level of effect in the absence of sensitizer, divided by the dose required to give the same effect in the presence of sensitizer, was maintained compared to single dosing (Hirst et al., 1982) and in others there was a loss of enhancement (McNally et al., 1983; Twentyman & Workman, 1983; Randhawa et al., 1985) . The administration of the drug combination in the form of a fractionated regime using higher doses, with intervals of the order of 1 day or more did however result in the maintenance of SER in several systems (Hill & Siemann, 1984; McNally et al., 1983; Randhawa, unpublished longer intervals between MISO doses allow recovery of the vasculature between fractions, consequently maintaining the SER. Conversely, during chronic dosing experiments, MISO levels were never high enough to achieve the required vascular effect and therefore no sensitization was observed. Whether this hypothesis is correct or not, it is clear from our findings that experiments on murine tumours carried out with high doses of MISO must be interpreted cautiously. We have recently carried out similar blood flow measurements on these same tumour models after treatment with the lipophilic radiosensitizer Ro-03-8799, which also potentiates several alkylating agents and nitrosoureas (Sheldon & Gibson, 1984) . We found that at 2 h after doses of 1,000mgkg-1 there was a 40% reduction in blood flow in the SaFA tumour but little or no change in the CaNT (Murray & Randhawa, unpublished) . Again this is probably due to peripheral vasoconstriction associated with a drop in core temperature. Tamulevicius et al. (1987) reported a drop of as much as 6'C in core temperature in mice after treatment with Ro-03-8799 at doses of 1,000 mg kg-1. Therefore this phenomenon of decreased tumour blood flow is not peculiar to MISO and must be considered as a possible component of any therapeutic effects seen with nitroimidazole sensitizers. Indeed these results have wider implications in terms of the specific control of blood flow in tumours. The use of agents which can increase the half-life of other cytotoxins in the tumour may provide a novel adjunct to conventional forms of therapy.
